Mara Goldstein

Stock Analyst at Mizuho

(2.80)
# 1,958
Out of 5,044 analysts
77
Total ratings
44.83%
Success rate
8.17%
Average return

Stocks Rated by Mara Goldstein

Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32$30
Current: $10.51
Upside: +185.44%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30$10
Current: $2.19
Upside: +356.62%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9$8
Current: $8.85
Upside: -9.60%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51$42
Current: $19.88
Upside: +111.27%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59$50
Current: $14.25
Upside: +250.88%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.51
Upside: +233.09%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82$77
Current: $91.65
Upside: -15.98%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8$7
Current: $2.44
Upside: +186.89%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12$8
Current: $1.49
Upside: +436.91%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20$12
Current: $0.53
Upside: +2,146.35%
Reiterates: Neutral
Price Target: $90
Current: $60.92
Upside: +47.73%
Reiterates: Neutral
Price Target: $3.5
Current: $7.59
Upside: -53.89%
Reiterates: Buy
Price Target: $360
Current: $2.10
Upside: +17,042.86%
Upgrades: Buy
Price Target: $10$20
Current: $6.49
Upside: +208.17%
Reiterates: Buy
Price Target: $130
Current: $87.03
Upside: +49.37%
Maintains: Neutral
Price Target: $4$2
Current: $3.32
Upside: -39.76%
Maintains: Buy
Price Target: $18$12
Current: $1.54
Upside: +679.22%
Upgrades: Buy
Price Target: $9
Current: $0.06
Upside: +15,444.04%
Reiterates: Overweight
Price Target: $14$20
Current: $61.97
Upside: -67.73%
Downgrades: Neutral
Price Target: $34$48
Current: $8.78
Upside: +446.70%
Downgrades: Neutral
Price Target: n/a
Current: $27.06
Upside: -
Maintains: Overweight
Price Target: $12$14
Current: $5.11
Upside: +173.97%